Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Acta Neurochir (Wien) ; 164(5): 1365-1373, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35257217

RESUMEN

BACKGROUND: Primary CNS lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma (NHL) that occurs in the CNS (e.g. brain, meninges, spinal cord, cerebrospinal fluid, or intraocular involvement) in the absence of systemic NHL. Tumor resection does not improve survival, and neurosurgical intervention is generally limited to stereotactic biopsy to provide a histopathological diagnosis. OBJECTIVE: The objective of this single-center study was to evaluate the management and outcome of PCNSL patients diagnosed by biopsy, using overall survival and progression-free survival as endpoints. METHODS: At our department of neurosurgery, 140 patients were diagnosed with PCNSL by biopsy between January 1, 2009, and December 31, 2018. Of these, 37 patients were included in the study and were divided into three groups according to their postoperative therapy. RESULTS: Median OS was 35.7 months for the intensive treatment group, 29.5 months for the moderate treatment group, and 8.6 months for the palliative treatment group. The intensive and moderate treatment groups had similar progression-free survival, while the palliative treatment group had poor overall and progression-free survival. Six patients were long-term survivors (> 80 months). Age under 65 years was the main significant parameter affecting overall survival. CONCLUSION: In this cohort, patients with PCNSL had an overall fair prognosis if they (1) were under 65 years old, (2) had a performance score < 2 at the time of diagnosis, and (3) received either intensive or moderate chemotherapeutic treatment. Biopsy is still the primary diagnostic tool; other methods have been investigated but are not yet recommended.


Asunto(s)
Neoplasias del Sistema Nervioso Central , Linfoma no Hodgkin , Anciano , Encéfalo/patología , Neoplasias del Sistema Nervioso Central/diagnóstico , Neoplasias del Sistema Nervioso Central/terapia , Estudios de Cohortes , Humanos , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/patología , Linfoma no Hodgkin/terapia , Procedimientos Neuroquirúrgicos/métodos , Pronóstico , Supervivencia sin Progresión , Estudios Retrospectivos , Resultado del Tratamiento
2.
Surgeon ; 18(6): 344-348, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32044289

RESUMEN

INTRODUCTION: Glioblastoma has a high mortality rate. Current treatment includes largest possible surgical resection of the tumour using neuronavigation and fluorescence to better identify tumour tissue. In recent years, sodium fluorescein has been reintroduced in neurosurgery as a fluorescence to increase the resection rate. In this study we aimed to measure the surgeons experience of using sodium fluorescein to locate and remove tumour tissue. Furthermore we describe a case of sodium fluorescein tissue distribution. MATERIAL AND METHODS: 13 patients with glioblastoma and seven patients with cerebral metastases undergoing surgical resection were included. Surgery was performed using microscope alternating between white light and the YELLOW 560 filter, which visualized sodium fluorescein. Surgeons graded its usability in terms of location and removal on a scale from one to four. The resection rate was determined by neuroradiologists. Tissue samples obtained during surgery were analysed in relation to fluorescence and dysmorphic cells. RESULTS: Surgeons reported high usability in terms of location and removal of tumours using sodium fluorescein with medians of four in all groups, except for sub-total resections which had a median of three. Surgical complications were minimal and both resection rate and survival rate was within international standards. Histological analysis showed a visual correlation between tumorous tissue and intensity of fluorescence. CONCLUSION: Sodium fluorescence is an effective and useful tool for surgeons during fluorescence-guided surgery for the resection of glioblastoma and cerebral metastases.


Asunto(s)
Neoplasias Encefálicas/cirugía , Fluoresceína , Colorantes Fluorescentes , Glioblastoma/cirugía , Anciano , Anciano de 80 o más Años , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Estudios de Cohortes , Femenino , Glioblastoma/mortalidad , Glioblastoma/patología , Humanos , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina
3.
Acta Neurochir (Wien) ; 161(3): 555-565, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30756241

RESUMEN

BACKGROUND: This study aimed to investigate the incidence of residual tumour after resection of brain metastases using early postoperative magnetic resonance imaging (MRI) and the influence of residual tumour on overall patient survival. METHODS: Data from 72 consecutive adult patients undergoing surgery for cerebral metastases over an 18-month study period were retrospectively collected. Early postoperative MRI was used to determine the presence of postoperative residual tumour. Patients were divided into three groups according to the presence of tumour remnant on early postoperative MRI: "no residual tumour", "non-measurable residual tumour" and "measurable residual tumour". Survival analysis (mean estimate survival time) was performed using the Kaplan-Meier and log-rank (mantel cox) tests and compared between groups. Surgical reports were evaluated with regard to the surgeon statement about intraoperative extent of resection (EOR) and compared with the presence of tumour remnant found on the early postoperative MRI. RESULTS: Sixty-eight procedures were followed by early postoperative MRI. MRI verified the presence of "measurable residual tumour" following 15 procedures (22%). MRI confirmed complete resection in 57%. Gross total resection was described by the operating surgeon in 85% of the procedures. There was a significant difference in survival time after surgery between the group having no residual tumour on MRI and the group with measurable residual tumour (p = 0.025). This difference could not be explained by the differences in postoperative radiation therapy. The longest survival was found in patients with non-measurable and no residual tumour on early postoperative MRI, who also received postoperative radiotherapy. CONCLUSION: Residual tumour was seen on MRI after 22% of the procedures. The intraoperative assessment of EOR performed by the surgeon diverged from the early postoperative MRI in 40% of procedures. Correct assessment of residual tumour thus requires early postoperative MRI. Measurable residual tumour on early postoperative MRI was associated with shorter overall survival independent on postoperative radiotherapy.


Asunto(s)
Neoplasias Encefálicas/cirugía , Imagen por Resonancia Magnética/métodos , Complicaciones Posoperatorias/epidemiología , Adulto , Anciano , Neoplasias Encefálicas/diagnóstico por imagen , Neoplasias Encefálicas/secundario , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Residual , Procedimientos Neuroquirúrgicos/efectos adversos , Procedimientos Neuroquirúrgicos/métodos , Complicaciones Posoperatorias/diagnóstico por imagen , Análisis de Supervivencia
4.
Ugeskr Laeger ; 177(26)2015 Jun 22.
Artículo en Danés | MEDLINE | ID: mdl-26550627

RESUMEN

Thrombosis of the cerebral sinuses most often affects younger adults. Headache is a common complaint and can be accom­panied by vomiting and papilloedema. The diagnosis rests on magnetic resonance imaging and the treatment consists of heparin or low-molecular weight heparin followed by vitamin K antagonists for three months or more. In fulminant cases local thrombolysis is administered, while symptomatic treatment for increased intracranial pressure is given. In retrospective analyses this approach has been associated with a good outcome ­ even in cases treated by decompressive craniectomy.


Asunto(s)
Trombosis de los Senos Intracraneales , Adulto , Anticoagulantes/uso terapéutico , Heparina/uso terapéutico , Humanos , Angiografía por Resonancia Magnética , Imagen por Resonancia Magnética , Trombosis de los Senos Intracraneales/diagnóstico , Trombosis de los Senos Intracraneales/diagnóstico por imagen , Trombosis de los Senos Intracraneales/tratamiento farmacológico , Trombosis de los Senos Intracraneales/fisiopatología , Vitamina K/antagonistas & inhibidores , Adulto Joven
5.
Ugeskr Laeger ; 176(33)2014 Aug 11.
Artículo en Danés | MEDLINE | ID: mdl-25293408

RESUMEN

Thrombosis of the cerebral sinuses most often affects younger adults. Headache is a common complaint and can be accompanied by vomiting and papilloedema. The diagnosis rests on magnetic resonance imaging and the treatment consists of heparin or low-molecular weight heparin followed by vitamin K antagonists for three months or more. In fulminant cases local thrombolysis is administered, while symptomatic treatment for increased intracranial pressure is given. In retrospective analyses this approach has been associated with a good outcome - even in cases treated by decompressive craniectomy.


Asunto(s)
Trombosis de los Senos Intracraneales , Adulto , Anticoagulantes/uso terapéutico , Heparina/uso terapéutico , Humanos , Imagen por Resonancia Magnética , Trombosis de los Senos Intracraneales/diagnóstico , Trombosis de los Senos Intracraneales/tratamiento farmacológico , Trombosis de los Senos Intracraneales/fisiopatología , Vitamina K/antagonistas & inhibidores , Adulto Joven
6.
Ugeskr Laeger ; 174(10): 630-3, 2012 Mar 05.
Artículo en Danés | MEDLINE | ID: mdl-22395010

RESUMEN

Recent research has revealed the existence of a class of small non-coding RNAs, known as microRNAs. These microRNAs are deregulated in various cancers including gliomas. MicroRNAs have been suggested to be important in cancer stem cell biology and in proliferation and chemosensitivity of cancer cells. This makes microRNAs obvious targets for novel therapeutic strategies. In the present article we focus on the role of microRNAs in cancer cells and cancer stem cells as well as the possible therapeutic approaches exploiting this knowledge to improve future glioma therapy.


Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Glioma/tratamiento farmacológico , MicroARNs/genética , Antineoplásicos/administración & dosificación , Neoplasias Encefálicas/genética , Convección , Sistemas de Liberación de Medicamentos/métodos , Regulación Neoplásica de la Expresión Génica/genética , Glioblastoma/tratamiento farmacológico , Glioblastoma/genética , Glioma/genética , Humanos , MicroARNs/efectos de los fármacos , MicroARNs/fisiología , Células Madre Neoplásicas/efectos de los fármacos , Células Madre Neoplásicas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA